Table 2. Mortality counts by disease endpoint in the Canadian and Massachusetts cohorts, in relation to dose range, attained age range, lag period from start of follow-up to entry into analysis cohort.

Endpoint/type of circulatory disease	ICD9 codes	Number of deaths/person years
		Canada	Massachusetts	Total
Lung dose < 0.5 Gy, age < 100, lag 5 years
Cerebrovascular disease	430–438	1192	369	1561
Ischaemic heart disease	410–414	4876	1534	6410
Hypertensive heart disease	401–405	181	63	244
Heart disease apart from IHD + hypertensive	390–400, 406–409, 415–429	926	383	1309
All other circulatory disease apart from heart + cerebrovascular	439–459	518	167	685
All circulatory disease	390–459	7693	2516	10,209
Person years follow-up		1,179,270	247,711	1,426,981
Lung dose unrestricted, age < 100, lag 5 years
Cerebrovascular disease	430–438	1481	472	1953
Ischaemic heart disease	410–414	6211	1947	8158
Hypertensive heart disease	401–405	234	89	323
Heart disease apart from IHD + hypertensive	390–400, 406–409, 415–429	1182	497	1679
All other circulatory disease apart from heart + cerebrovascular	439–459	659	211	870
All circulatory disease	390–459	9767	3216	12,983
Person years follow-up		1,599,120	345,921	1,945,041
Lung dose unrestricted, age unrestricted, lag 0 years
Cerebrovascular disease	430–438	1585	493	2078
Ischaemic heart disease	410–414	6516	2086	8602
Hypertensive heart disease	401–405	286	102	388
Heart disease apart from IHD + hypertensive	390–400, 406–409, 415–429	1330	543	1873
All other circulatory disease apart from heart + cerebrovascular	439–459	701	222	923
All circulatory disease	390–459	10,418	3446	13,864
Person years follow-up		1,904,580	405,193	2,309,773